ENDRA Life Sciences to Showcase TAEUS(TM) Liver Application at Three Global Liver and Imaging Conferences in November 2018
ENDRA to Participate in The Liver Meeting® 2018 from November 9-13, the Interdisciplinary Ultrasound Congress 2018 from November 14-16 and the RSNA® 2018 Annual Meeting from November 25-30
ANN ARBOR, MI / ACCESSWIRE / October 24, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a developer of enhanced ultrasound technologies, will showcase its Thermo-Acoustic Enhanced Ultrasound (TAEUS™) liver application at several upcoming liver and imaging industry conferences in November 2018.
ENDRA's TAEUS technology, which uses RF energy to enhance ultrasound, is designed to provide information on human tissue composition, function and temperature in ways previously possible only on computed tomography (CT) & magnetic resonance imaging (MRI) – but at a fraction of the cost, and at the point of patient care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD), which affects over one billion people globally and which has no practical diagnostic tools.
"We look forward to attending these premier industry conferences in November as we prepare for TAEUS' anticipated commercial launch in Europe in 2019," said Francois Michelon, CEO of ENDRA Life Sciences. "Our formal presence at these events will allow us to share the status of our developing TAEUS liver technology, build new clinical relationships and collect valuable feedback from clinical thought leaders in hepatology and radiology," concluded Michelon.
The Liver Meeting 2018 Summit
Date: November 9 - 13, 2018
Location: Moscone Center North and South in San Francisco, California
Host: American Association for the Study of Liver Diseases (AASLD)
ENDRA Booth: #246
Website: https://www.aasld.org/events-professional-development/liver-meeting
During The Liver Meeting® 2018, more than 9,500 hepatologists and hepatology health professionals from around the world will gather in San Francisco, CA to exchange the latest liver disease research, discuss treatment outcomes, and interact with colleagues at the annual, must-attend event in the science and practice of hepatology.
The Interdisciplinary Ultrasound Congress 2018
Date: November 14 - 16, 2018
Location: Congress Center in Basel, Switzerland
Host: The Swiss Society for Ultrasound in Medicine (SSUM)
ENDRA Booth: #240
Website: https://ultraschall2018.ch/
The Interdisciplinary Ultrasound Congress is focused on the development of ultrasound, combining almost all disciplines within human medicine in a unique way. From a formerly small ultrasound family a large user population has developed that is fascinated and inspired by ultrasound and its many different uses beyond obstetrics. Over three days, 1,500 participants from Switzerland, Germany, Austria and elsewhere are expected to present new products and build customer relationships.
RSNA 2018 Annual Meeting
Date: November 25 - 30, 2018
Location: McCormick Place in Chicago, Illinois
Host: Radiological Society of North America (RSNA)
ENDRA Booth: #1153
Website: http://www.rsna.org/Annual-Meeting/
The Radiological Society of North America (RSNA®) is an international society of radiologists, medical physicists and other medical professionals with more than 54,000 members from 136 countries across the globe. RSNA hosts the world's premier radiology forum, drawing approximately 55,000 attendees annually to McCormick Place in Chicago, and publishes two top peer-reviewed journals: Radiology, the highest-impact scientific journal in the field, and RadioGraphics, the only journal dedicated to continuing education in radiology.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. ("ENDRA") (NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.
About Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100 billion annually. NAFLD is often asymptomatic and, if left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding expectations concerning ENDRA's ability to secure regulatory approvals; anticipated product pricing; expectations with respect to current and future partnerships; estimates of the timing of future events and achievements; and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, the following: our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us
SOURCE: ENDRA Life Sciences Inc.
